mRNA, TFF, And Next Steps To Tackle mRNA Therapeutic Challenges

Which specific steps do you consider the most challenging in mRNA therapeutic development? Hundreds of viewers tackled the question during the Bioprocess Online Live digital event Risk Reduction In mRNA Therapeutic Development. Expert panelists Patrick Baumhof, SVP of Technology at CureVac and Christian Dohmen, Senior Director of Formulation & Aerosol Research at Ethris provided commentary, addressed audience questions on tangential flow filtration and lyophilization, and shared thoughts on new technologies in mRNA therapeutic development.